CN114127068A - 嘧啶衍生物的优势盐型及其晶型 - Google Patents

嘧啶衍生物的优势盐型及其晶型 Download PDF

Info

Publication number
CN114127068A
CN114127068A CN202080052155.3A CN202080052155A CN114127068A CN 114127068 A CN114127068 A CN 114127068A CN 202080052155 A CN202080052155 A CN 202080052155A CN 114127068 A CN114127068 A CN 114127068A
Authority
CN
China
Prior art keywords
compound
crystalline form
xrpd pattern
diffraction peaks
dsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080052155.3A
Other languages
English (en)
Inventor
陈小新
刘呈武
刘卓伟
谭珍友
刘志强
程志伟
龙超峰
黄嘉骏
周光强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Raynovent Biotech Co Ltd
Original Assignee
Guangdong Raynovent Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Raynovent Biotech Co Ltd filed Critical Guangdong Raynovent Biotech Co Ltd
Publication of CN114127068A publication Critical patent/CN114127068A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

嘧啶衍生物的钠盐及其一系列晶型，该系列晶型表现为具有较好的成药性(如稳定性、流动性、可压性等)，为后续药品开发提供多种原料药选择。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN202080052155.3A 2019-07-22 2020-06-24 嘧啶衍生物的优势盐型及其晶型 Pending CN114127068A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910660153 2019-07-22
CN2019106601531 2019-07-22
PCT/CN2020/097967 WO2021012864A1 (zh) 2019-07-22 2020-06-24 嘧啶衍生物的优势盐型及其晶型

Publications (1)

Publication Number Publication Date
CN114127068A true CN114127068A (zh) 2022-03-01

Family

ID=74193127

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080052155.3A Pending CN114127068A (zh) 2019-07-22 2020-06-24 嘧啶衍生物的优势盐型及其晶型

Country Status (6)

Country Link
US (1) US20220380363A1 (zh)
EP (1) EP3992192A4 (zh)
JP (1) JP7450017B2 (zh)
CN (1) CN114127068A (zh)
TW (1) TWI752553B (zh)
WO (1) WO2021012864A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089261A1 (zh) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458408A (zh) * 2009-06-17 2012-05-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018041263A1 (zh) * 2016-09-05 2018-03-08 广东众生药业股份有限公司 抗流感病毒嘧啶衍生物
WO2019170067A1 (zh) * 2018-03-05 2019-09-12 广东众生睿创生物科技有限公司 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
KR20140014110A (ko) * 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
AU2015298876B2 (en) * 2014-08-08 2020-02-13 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458408A (zh) * 2009-06-17 2012-05-16 沃泰克斯药物股份有限公司 流感病毒复制抑制剂
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018041263A1 (zh) * 2016-09-05 2018-03-08 广东众生药业股份有限公司 抗流感病毒嘧啶衍生物
CN109790159A (zh) * 2016-09-05 2019-05-21 广东众生睿创生物科技有限公司 抗流感病毒嘧啶衍生物
WO2019170067A1 (zh) * 2018-03-05 2019-09-12 广东众生睿创生物科技有限公司 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Also Published As

Publication number Publication date
JP2022540207A (ja) 2022-09-14
EP3992192A1 (en) 2022-05-04
US20220380363A1 (en) 2022-12-01
JP7450017B2 (ja) 2024-03-14
TW202116769A (zh) 2021-05-01
TWI752553B (zh) 2022-01-11
EP3992192A4 (en) 2022-08-17
WO2021012864A1 (zh) 2021-01-28

Similar Documents

Publication Publication Date Title
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
CN111819177B (zh) 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法
CN114149476A (zh) 一种核糖核苷类似物的多晶型物、其制备方法及应用
WO2019228485A1 (zh) 一种甲磺酸乐伐替尼新晶型及其制备方法
JP7274000B2 (ja) ペラミビル三水和物の新規な製造方法及びその水系乾燥
TWI672305B (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
CN106795104A (zh) 改进的制备高纯度二甲双胍的方法
CN114127068A (zh) 嘧啶衍生物的优势盐型及其晶型
CN106905319B (zh) 取代苯磺酰苦参丁烷或其盐酸盐的制备方法
CN114555561A (zh) 作为rho激酶抑制剂的苯并吡唑类化合物的盐型、晶型及其制备方法
JP6965274B2 (ja) ナトリウム−グルコース結合輸送体阻害剤のアミン溶媒和物、その調製方法およびその適用
WO2022089261A1 (zh) 一种嘧啶衍生物的晶型及其制备方法
WO2017096907A1 (zh) 一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用
CN108822054B (zh) 盐酸奥达特罗晶型c及其制备方法
CN114644681B (zh) 一种奈玛特韦异丙醇溶剂化物晶型及其制备方法
CN111320568A (zh) 一种匹莫范色林的新晶型及其制备方法
CN109096218B (zh) 盐酸奥达特罗晶型a及其制备方法
CN115583952B (zh) 5型磷酸二酯酶抑制剂的多晶物及其制备方法和应用
CN115298172B (zh) 一种作为smo抑制剂化合物的盐型、晶型及其制备方法
CN108069983A (zh) 一种噁唑烷酮类化合物的晶型及其制备方法和应用
WO2015123801A1 (zh) 一种6-(4-氯苯氧基)-四唑并[5,1-a]酞嗪的多晶型制备方法及其应用
CN113603673A (zh) 一种盐酸度洛西汀的晶型、其制备方法及其应用
CN107406372A (zh) 米诺环素碱的新的多晶型形式及其制备方法
CN107266518B (zh) 一种糠酸莫米松晶型及其制备方法
CN116410170A (zh) 一种淫羊藿素共晶体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination